Compare Immunovant Inc. Common Stock (IMVT) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Xpeng Inc - ADR — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.25B), while Xpeng Inc - ADR trades at $9.71 (market cap $9.16B). The key difference: Xpeng Inc - ADR is the larger of the two by market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Xpeng Inc - ADR for 80 Days on average.
| IMVT | XPEV | |
|---|---|---|
Market Cap | $6.25B | $9.16B |
Volume | 1,755,411 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $28.07 |
52-Week Low | $17.03 | $9.25 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $5.35B | $11.09B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XPeng (XPEV) trades at $9.58, showing minimal daily movement (+0.21%). The stock faces bearish technical signals with oversold RSI readings. Fundamentally, while revenue grew significantly to $76.72B in 2025, the company remains unprofitable with a net loss of $1.14B. Recent quarterly earnings show mixed results with one beat and two misses. Positive developments include strong September 2026 deliveries of 41,256 vehicles and upcoming global launches of new AI-enabled models.
The investment case balances growth potential against persistent losses. Analyst consensus is bullish with a $17.55 price target (83% upside), but execution risks in the competitive EV market and negative profitability metrics warrant caution. The expansion into humanoid robotics and AI technology represents a strategic diversification that could drive future valuation if successfully commercialized.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
